
    
      This Phase II randomized study is to determine the efficacy and toxicity of toripalimab plus
      neoadjuvant chemotherapy combined with chemoradiotherapy for locally advanced unresectable
      esophageal squamous cell carcinoma.

      All patients were planned to receive 2 cycle of toripalimab plus paclitaxel/nedaplatin as
      neoadjuvant therapy. Then they all receive radical dose of chest radiation and concurrent
      chemotherapy of capecitabine (PO 1000 mg/m2, bid, d1-d14, q3w).
    
  